<DOC>
	<DOC>NCT01514851</DOC>
	<brief_summary>To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized, double-blind, parallel group study in comparison with Calcium carbonate.</brief_summary>
	<brief_title>Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Predialysis serum phosphate levels: ≧5.6 mg/dL and &lt;11.0 mg/dL at 1 week after the initiation of the washout period. Outpatient Undergoing hemodialysis three times per week for at least previous 3 consecutive months Predialysis serum phosphate levels of ≧10.0 mg/dL at the start of the washout period or ≧11.0 mg/dL at 1 week after Corrected serum calcium level of &lt;7.0 mg/dL or ≧11.0 mg/dL at the start of the washout period and/or 1 week after Serum intact PTH (Parathyroid) of ≧1000 pg/mL at the start of the washout period Pregnant woman, or lactating mother Significant gastrointestinal disorders including known acute peptic ulcer Liver dysfunction History of cardiovascular or cerebrovascular diseases Requiring treatment for hypothyroidism</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Hyperphosphatemia in ESRD (End Stage Renal Disease) patients on dialysis</keyword>
</DOC>